カテプシン阻害剤の世界市場レポート 2025年

カテプシン阻害剤の市場規模は、今後数年で急成長が見込まれます。2029年には12億6,000万米ドルに成長し、CAGRは10.8%となります。予測期間の成長は、標的療法の開発、神経変性疾患の治療法の増加、研究開発資金の増加、精密医療への需要の高まり、感染症治療への応用拡大などに起因すると考えられます。この期間の主な動向としては、選択的カテプシン阻害剤の台頭、バイオテクノロジー企業間の提携、経口剤への注力、創薬におけるAIの活用、希少疾患の治療薬への拡大などが挙げられます。

神経変性疾患の罹患率の増加は、カテプシン阻害剤市場の拡大を促進すると予想されます。神経変性疾患は、進行性で、多くの場合不可逆的な疾患であり、中枢神経系の神経細胞が徐々に劣化または死滅することを特徴とし、特に脳に影響を及ぼします。これらの疾患の増加は、高齢化社会と密接な関係があります。平均寿命が延びるにつれて、アルツハイマー病やパーキンソン病などの疾患がより一般的になり、ヘルスケアシステムにさらなる負担を強いています。カテプシン阻害剤は、アミロイドベータ（AB）産生と神経炎症を調節する能力があるため、神経変性疾患の潜在的治療薬として研究されています。例えば、Alzheimer's Associationによると、2024年には65歳以上のアメリカ人の約690万人がアルツハイマー型認知症を患っており、この数は2060年までにほぼ倍の1,380万人になると予想されています。その結果、神経変性疾患の有病率の増加がカテプシン阻害剤の需要を牽引しています。

カテプシン阻害剤市場の企業は、創薬におけるイノベーションを推進し、製品ポートフォリオを拡大し、市場参入を加速するために戦略的パートナーシップを結んでいます。これらの提携は、補完的な専門知識やリソースを活用し、臨床試験や薬事承認の成功率を高めることを目的としています。例えば、2024年6月、日本を拠点とする創薬企業のAlivexisは、スイスを拠点とするバイオテクノロジー企業のMelodia Therapeuticsと独占的ライセンス契約を締結しました。この契約は、新規カテプシンC阻害剤MDI-0151の開発、製造、商業化に関する全世界での権利を付与するものです。MDI-0151は、AlivexisのMOD-A探索プログラムで同定されたもので、ANCA関連血管炎などの好中球を駆動源とする炎症性疾患をターゲットとします。Melodiaは、臨床的概念実証を確立するためのフェーズ1/2a試験に向けて、IND取得に向けた活動を開始する予定です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のカテプシン阻害剤のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のカテプシン阻害剤市場：成長率分析
• 世界のカテプシン阻害剤市場の実績：規模と成長、2019～2024年
• 世界のカテプシン阻害剤市場の予測：規模と成長、2024～2029年、2034年
• 世界のカテプシン阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のカテプシン阻害剤市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 低分子阻害剤
• ペプチド阻害剤
• モノクローナル抗体
• 世界のカテプシン阻害剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• がん治療
• 自己免疫疾患
• 炎症性疾患
• 神経変性疾患
• その他
• 世界のカテプシン阻害剤市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• オンライン薬局
• 小売薬局
• 病院・クリニック
• 世界のカテプシン阻害剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 製薬会社
• 学術研究機関
• 契約研究機関（CRO）
• 世界のカテプシン阻害剤市場：低分子阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 可逆的阻害剤
• 不可逆的阻害剤
• 合成化合物
• 天然物由来阻害剤
• 世界のカテプシン阻害剤市場：ペプチド阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 直鎖ペプチド
• 環状ペプチド
• 修飾ペプチド
• ペプチド模倣薬
• 世界のカテプシン阻害剤市場：モノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ヒト化モノクローナル抗体
• 完全ヒトモノクローナル抗体
• キメラモノクローナル抗体
• 二重特異性抗体

第7章 地域別・国別分析

• 世界のカテプシン阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のカテプシン阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• カテプシン阻害剤市場：競合情勢
• カテプシン阻害剤市場：企業プロファイル
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
  • AddLife AB Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• BioVision
• R&D Systems Inc.
• Cayman Chemical
• Selleck Chemicals
• Santa Cruz Animal Health
• Tocris Bioscience
• Virobay Inc.
• MedChemExpress
• BOC Sciences
• Biorbyt Ltd
• GlpBio Technology
• Echelon Biosciences
• AG Scientific
• ApexBio Technology
• OXiGENE Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• カテプシン阻害剤市場2029年：新たな機会を提供する国
• カテプシン阻害剤市場2029年：新たな機会を提供するセグメント
• カテプシン阻害剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cathepsin inhibitors are compounds that block the activity of cathepsins, enzymes involved in various biological processes such as protein degradation and cell regulation. These inhibitors are being studied for their potential to treat diseases by modulating cathepsin activity. Their ability to target specific biological mechanisms positions them as promising candidates for therapeutic development.

The main types of cathepsin inhibitors include small molecule inhibitors, peptide inhibitors, and monoclonal antibodies. Small molecule cathepsin inhibitors are low molecular weight compounds specifically designed to block the activity of cathepsin enzymes. These inhibitors are applied in the treatment of cancer, autoimmune diseases, inflammatory disorders, neurodegenerative conditions, and other therapeutic areas. Distribution channels for these products include online pharmacies, retail pharmacies, and hospitals and clinics, serving end users such as pharmaceutical companies, academic and research institutions, and contract research organizations (CROs).

The cathepsin inhibitor market research report is one of a series of new reports from The Business Research Company that provides cathepsin inhibitor market statistics, including cathepsin inhibitor industry global market size, regional shares, competitors with a cathepsin inhibitor market share, detailed cathepsin inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the cathepsin inhibitor industry. This cathepsin inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cathepsin inhibitor market size has grown rapidly in recent years. It will grow from$0.76 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period can be attributed to the rising incidence of cancer, the increasing prevalence of inflammatory diseases, growing investments in drug discovery, advancements in protease research, and the expanding use of cathepsin inhibitors in treating bone disorders.

The cathepsin inhibitor market size is expected to see rapid growth in the next few years. It will grow to$1.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to the development of targeted therapies, the rise in treatments for neurodegenerative diseases, increased funding for research and development, growing demand for precision medicine, and expanding applications in infectious disease treatment. Key trends during this period include the emergence of selective cathepsin inhibitors, collaborations between biotech firms, a focus on oral drug formulations, the use of AI in drug discovery, and the expansion into therapeutics for rare diseases.

The growing incidence of neurodegenerative disorders is expected to fuel the expansion of the cathepsin inhibitor market. Neurodegenerative disorders are progressive, often irreversible conditions characterized by the gradual deterioration or death of neurons in the central nervous system, particularly impacting the brain. The rise in these disorders is closely linked to the aging population. As life expectancy increases, conditions such as Alzheimer's and Parkinson's become more common, adding further strain to healthcare systems. Cathepsin inhibitors are being studied as potential therapeutic agents for neurodegenerative diseases due to their ability to modulate amyloid-beta (AB) production and neuroinflammation. For example, according to the Alzheimer's Association, in 2024, about 6.9 million Americans aged 65 and older are living with Alzheimer's dementia, and this number is expected to nearly double to 13.8 million by 2060. As a result, the increasing prevalence of neurodegenerative disorders is driving the demand for cathepsin inhibitors.

Companies in the cathepsin inhibitor market are forming strategic partnerships to drive innovation in drug discovery, expand their product portfolios, and speed up market entry. These collaborations aim to leverage complementary expertise and resources to enhance the success rates of clinical trials and regulatory approvals. For example, in June 2024, Alivexis, a Japan-based drug discovery company, entered into an exclusive licensing agreement with Melodia Therapeutics, a Switzerland-based biotech firm. The agreement grants worldwide rights to the development, manufacturing, and commercialization of MDI-0151, a novel cathepsin C inhibitor. MDI-0151, identified in Alivexis' MOD-A discovery program, is targeted at neutrophil-driven inflammatory diseases such as ANCA-associated vasculitis. Melodia plans to initiate IND-enabling activities in preparation for Phase 1/2a studies to establish clinical proof of concept.

In April 2022, AddLife AB, a Swedish life science company, acquired BioCat GmbH for an undisclosed amount. This acquisition was aimed at strengthening AddLife's presence in the DACH (Germany, Austria, and Switzerland) region and expanding its Labtech business area through increased collaboration with its existing European subsidiaries. BioCat GmbH, a Germany-based life sciences company, specializes in providing cathepsin K inhibitors for use in biological research and drug development.

Major players in the cathepsin inhibitor market are Merck KGaA, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bio-Techne Corporation, AddLife AB, BioVision, R&D Systems Inc., Cayman Chemical, Selleck Chemicals, Santa Cruz Animal Health, Tocris Bioscience, Virobay Inc., MedChemExpress, BOC Sciences, Biorbyt Ltd, GlpBio Technology, Echelon Biosciences, AG Scientific, ApexBio Technology, and OXiGENE Inc.

North America was the largest region in the cathepsin Inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cathepsin inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cathepsin inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cathepsin inhibitor market consists of sales of small-molecule inhibitors, prescription drugs, research-grade inhibitors, and therapeutic formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cathepsin Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cathepsin inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cathepsin inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cathepsin inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Small Molecule Inhibitors; Peptide Inhibitors; Monoclonal Antibodies
• 2) By Application: Cancer Treatment; Autoimmune Diseases; Inflammatory Diseases; Neurodegenerative Disorders; Other Therapeutic Areas
• 3) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Hospitals And Clinics
• 4) By End User: Pharmaceutical Companies; Academic And Research Institutes; Contract Research Organizations (CROs)
• Subsegments:
• 1) Small Molecule Inhibitors: Reversible Inhibitors; Irreversible Inhibitors; Synthetic Compounds; Natural Product-Derived Inhibitors
• 2) Peptide Inhibitors: Linear Peptides; Cyclic Peptides; Modified Peptides; Peptidomimetics
• 3) Monoclonal Antibodies: Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Bispecific Antibodies
• Companies Mentioned: Merck KGaA; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Bio-Techne Corporation; AddLife AB
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cathepsin Inhibitor Market Characteristics

3. Cathepsin Inhibitor Market Trends And Strategies

4. Cathepsin Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cathepsin Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cathepsin Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cathepsin Inhibitor Market Growth Rate Analysis
• 5.4. Global Cathepsin Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cathepsin Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cathepsin Inhibitor Total Addressable Market (TAM)

6. Cathepsin Inhibitor Market Segmentation

• 6.1. Global Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Inhibitors
• Peptide Inhibitors
• Monoclonal Antibodies
• 6.2. Global Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Treatment
• Autoimmune Diseases
• Inflammatory Diseases
• Neurodegenerative Disorders
• Other Therapeutic Areas
• 6.3. Global Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Pharmacies
• Retail Pharmacies
• Hospitals And Clinics
• 6.4. Global Cathepsin Inhibitor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Academic And Research Institutes
• Contract Research Organizations (CROs)
• 6.5. Global Cathepsin Inhibitor Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reversible Inhibitors
• Irreversible Inhibitors
• Synthetic Compounds
• Natural Product-Derived Inhibitors
• 6.6. Global Cathepsin Inhibitor Market, Sub-Segmentation Of Peptide Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Linear Peptides
• Cyclic Peptides
• Modified Peptides
• Peptidomimetics
• 6.7. Global Cathepsin Inhibitor Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Humanized Monoclonal Antibodies
• Fully Human Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• Bispecific Antibodies

7. Cathepsin Inhibitor Market Regional And Country Analysis

• 7.1. Global Cathepsin Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cathepsin Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cathepsin Inhibitor Market

• 8.1. Asia-Pacific Cathepsin Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cathepsin Inhibitor Market

• 9.1. China Cathepsin Inhibitor Market Overview
• 9.2. China Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cathepsin Inhibitor Market

• 10.1. India Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cathepsin Inhibitor Market

• 11.1. Japan Cathepsin Inhibitor Market Overview
• 11.2. Japan Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cathepsin Inhibitor Market

• 12.1. Australia Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cathepsin Inhibitor Market

• 13.1. Indonesia Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cathepsin Inhibitor Market

• 14.1. South Korea Cathepsin Inhibitor Market Overview
• 14.2. South Korea Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cathepsin Inhibitor Market

• 15.1. Western Europe Cathepsin Inhibitor Market Overview
• 15.2. Western Europe Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cathepsin Inhibitor Market

• 16.1. UK Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cathepsin Inhibitor Market

• 17.1. Germany Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cathepsin Inhibitor Market

• 18.1. France Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cathepsin Inhibitor Market

• 19.1. Italy Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cathepsin Inhibitor Market

• 20.1. Spain Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cathepsin Inhibitor Market

• 21.1. Eastern Europe Cathepsin Inhibitor Market Overview
• 21.2. Eastern Europe Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cathepsin Inhibitor Market

• 22.1. Russia Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cathepsin Inhibitor Market

• 23.1. North America Cathepsin Inhibitor Market Overview
• 23.2. North America Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cathepsin Inhibitor Market

• 24.1. USA Cathepsin Inhibitor Market Overview
• 24.2. USA Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cathepsin Inhibitor Market

• 25.1. Canada Cathepsin Inhibitor Market Overview
• 25.2. Canada Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cathepsin Inhibitor Market

• 26.1. South America Cathepsin Inhibitor Market Overview
• 26.2. South America Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cathepsin Inhibitor Market

• 27.1. Brazil Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cathepsin Inhibitor Market

• 28.1. Middle East Cathepsin Inhibitor Market Overview
• 28.2. Middle East Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cathepsin Inhibitor Market

• 29.1. Africa Cathepsin Inhibitor Market Overview
• 29.2. Africa Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cathepsin Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. Cathepsin Inhibitor Market Competitive Landscape
• 30.2. Cathepsin Inhibitor Market Company Profiles
  • 30.2.1. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AddLife AB Overview, Products and Services, Strategy and Financial Analysis

31. Cathepsin Inhibitor Market Other Major And Innovative Companies

• 31.1. BioVision
• 31.2. R&D Systems Inc.
• 31.3. Cayman Chemical
• 31.4. Selleck Chemicals
• 31.5. Santa Cruz Animal Health
• 31.6. Tocris Bioscience
• 31.7. Virobay Inc.
• 31.8. MedChemExpress
• 31.9. BOC Sciences
• 31.10. Biorbyt Ltd
• 31.11. GlpBio Technology
• 31.12. Echelon Biosciences
• 31.13. AG Scientific
• 31.14. ApexBio Technology
• 31.15. OXiGENE Inc.

32. Global Cathepsin Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cathepsin Inhibitor Market

34. Recent Developments In The Cathepsin Inhibitor Market

35. Cathepsin Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 Cathepsin Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cathepsin Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cathepsin Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer